RecruitingPhase 2NCT06561347
Rare condition
Waldenström macroglobulinemia
14
studies recruiting now
as of 7 Sept 2026
202
studies registered in total
as of 7 Sept 2026
17
countries with a recruiting site
as of 7 Sept 2026
27 Nov 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 1 / Phase 2NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1 / Phase 2NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
RecruitingNCT05640102
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
RecruitingPhase 1NCT06708897
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 14 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Waldenström macroglobulinemia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Waldenström macroglobulinemia
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (MYD88).
Treatments being studied
2 approved treatments and 39 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Pirtobrutinib (Jaypirca)Approved: Zanubrutinib (Brukinsa)
Phase 3Rituximab (Blitzima)
Phase 3Dexamethasone (Aeroseb-dex)
Phase 3Cyclophosphamide (Cyclophosphamide)
Phase 3Ibrutinib (Imbruvica)
Phase 2Ixazomib Citrate (Ninlaro)
Phase 2Simvastatin (Flolipid)
Phase 2Ixazomib
Phase 2Sonrotoclax
+ 31 more in development
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).